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2 BOUSQUET ET ALAllergic rhinitis (AR) and asthma represent global health
problems for all age groups. Asthma and rhinitis frequently
coexist in the same subjects. Allergic Rhinitis and its Impact on
Asthma (ARIA)was initiatedduringaWorldHealthOrganization
workshop in 1999 (published in 2001).ARIAhas reclassifiedARas
mild/moderate-severe and intermittent/persistent. This
classification closely reflects patients’ needs and underlines the
close relationship between rhinitis and asthma. Patients,
clinicians, and other health care professionals are confrontedwith
various treatment choices for the management of AR. This
contributes to considerable variation in clinical practice, and
worldwide, patients, clinicians, andotherhealth care professionals
are facedwithuncertainty about the relativemerits anddownsides
of the various treatment options. In its 2010 Revision, ARIA
developed clinical practice guidelines for the management of AR
and asthma comorbidities based on the Grading of
Recommendation, Assessment, Development and Evaluation
(GRADE) system.ARIA isdisseminatedand implemented inmore
than 50 countries of the world. Ten years after the publication of
the ARIAWorld Health Organization workshop report, it is
important tomake a summary of its achievements and identify the
still unmet clinical, research, and implementation needs to
strengthen the 2011 European Union Priority on allergy and
asthma in children. (J Allergy Clin Immunol 2012;nnn:nnn-nnn.)
Key words: Rhinitis, asthma, Allergic Rhinitis and its Impact on
Asthma, allergy, GRADE
Allergic rhinitis (AR) and asthma frequently coexist in the
same subjects and represent a global health problem. Patients,
clinicians, and other health care professionals worldwide are
faced with the relative merits and downsides of the various
treatment options. Clinical practice guidelines for AR manage-
ment developed over the past 15 years1,2 have improved the care
of patients with AR.3
The outcomes of an expert workshop held at the World Health
Organization (WHO) in December 1999 (Allergic Rhinitis and its
Impact on Asthma [ARIA]) were published in 2001.4 The ARIA
workshop report was innovative in
d proposing a new AR classification using persistence and se-
verity of symptoms;
d promoting the concept of comorbidities in asthma and rhi-
nitis as a key factor for patients’ management;
d developing guidelines in collaboration with all stake-
holders, including primary care physicians and patients;
d including experts from developed and developing
countries;
d adopting an evidence-based approach for the first time in
guidelines on rhinitis5; and
d initiating global implementation among health care profes-
sionals and patients.
Finally, the International Primary Care Respiratory Group
guidelines on AR were based on the ARIAworkshop report.6,7
Guidelines must be updated. The ARIA update was published
in 20088 by using the same evidence-based model.5 This was a
continuous process preceded by a literature review of the aspects
not previously covered (eg, complementary and alternative med-
icine9 and sports10), the update on the links between rhinitis and
asthma,11 and prevention12 and treatment.13,14However, the transparent reporting of guidelines is needed to
facilitate understanding and acceptance. ARIA was the first
chronic respiratory disease guideline to adopt the Grading of
Recommendation, Assessment, Development and Evaluation
(GRADE) system, an advanced evidence evaluation methodol-
ogy. The ARIA revision was published in 2010.15
Ten years after publication of the ARIAWHOworkshop report,
it is important to make a summary of its achievements and
identify the still unmet clinical and research needs.SCIENTIFIC PUBLICATIONS USING THE ARIA
CLASSIFICATION
A Medline search carried out August 1, 2011, retrieved 251
original articles conducted in 43 countries that used the ARIA
classification of intermittent and persistent AR. These studies
have involvedmore than 170,000 subjects (see Table E1 in this ar-
ticle’s Online Repository at www.jacionline.org), including pre-
school children, but no study has specifically targeted the
elderly. The articles included epidemiologic studies in the general
population (cross-sectional16-23 and cohort24), observational
studies among primary care physicians and specialists, and inter-
ventional studies, including 5 large-scale, double-blind, placebo-
controlled trials.25-29 Three Cochrane Collaboration reviews
using the ARIA classification have been finalized,30-32 and others
are pending.THE ARIA CLASSIFICATION OF AR IS CLOSE TO
PATIENTS’ NEEDS
The classification of ARwas revised byARIA in 2001. Amajor
change was the introduction of the terms ‘‘intermittent’’ and
‘‘persistent.’’4 Previously, ARwas classified based on the time and
type of exposure and symptoms as seasonal, perennial, and occu-
pational.2,33 However, this classification is not entirely satisfac-
tory because of the following:
d In certain areas, pollens and molds are perennial aller-
gens,34 whereas house dust mites show seasonal trends.35
d Most patients are polysensitized to several different aller-
gens and exposed throughout the year.17,18,36,37
d In the general population, a large number of patients with
house dust mite allergy have intermittent rhinitis.17,18,35
d Because of the priming effect on the nasal mucosa induced
by low levels of pollen allergens38 and nasal minimal
persistent inflammation in patients with symptom-free
rhinitis,39 symptoms do not necessarily occur strictly in
conjunction with the allergen season.
d The ARIA classification appears to be closer to the pa-
tient’s needs than the previous one.17,40
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‘‘persistent’’ is the need to harmonize AR with asthma, rep-
resenting manifestations of the same condition in 2 parts of
the airways.41
The phenotypes of seasonal and perennial rhinitis cannot be
used interchangeably with the ARIA classification because they
do not represent the same stratum of disease. Thus ‘‘intermittent’’
and ‘‘persistent’’ are not synonymous with ‘‘seasonal’’ and
‘‘perennial.’’18,20,21,36,42 In 2008, the US rhinitis practice parame-
ters43 proposed the term ‘‘episodic’’ AR. This term has not been
validated, although it might refer to intermittent AR.COMORBIDITY BETWEEN ASTHMA AND RHINITIS
The links between rhinitis and asthma were identified 2
centuries ago. However, before the ARIA workshop, asthma
and rhinitis comorbidity was disregarded, and even in 2012, some
guidelines do not report these links properly. However, the ARIA
update literature review clearly supported the links between the
upper and the lower airways.11 Most patients with asthma (both
allergic and nonallergic) also have rhinitis, whereas 10% to
40% of patients with AR have asthma comorbidity.11 Some,36
but not all,44 studies suggest that asthma is more common in pa-
tients with moderate-to-severe persistent rhinitis than in those
with the other types of rhinitis. Strong interactions exist between
asthma and rhinitis because of occupational environments.45
Large studies have found a link between the severity and/or
control of both diseases in children and adults.46-49 Moreover, pa-
tients with severe uncontrolled asthma commonly have severe na-
sal disease (often chronic rhinosinusitis).50,51
Rhinitis is not usually the first symptom to occur in preschool
children during the atopic march.52 However, rhinitis in subjects
without asthma is a risk factor for asthma both in adults53 and
children.54 In adulthood, the development of asthma in patients
with rhinitis is often independent of allergy,55 whereas in child-
hood, it is frequently associated with allergy.54CLINICAL EFFECT OF THE ARIA CLASSIFICATION
Large observational cross-sectional studies have found that
severity (mild-moderate to severe) and persistence (intermittent/
persistent) are 2 separate and possibly independent components
of rhinitis.
In studies often carried out in primary care settings, adults or
children with moderate-to-severe rhinitis have a similar impair-
ment of quality of life or productivity irrespective of whether they
have intermittent or persistent rhinitis. Mean Rhinoconjunctivitis
Quality of Life Questionnaires or visual analog scale scores are
consistently higher in patients with moderate-to-severe rhinitis
than in patients with mild rhinitis.56-60SUBPHENOTYPING OF PATIENTS WITH AR
Severity is one of the phenotypic characteristics of allergic
disease that has received particular attention. Severity fluctuates
from year to year in relation to allergen exposure. Most
patients seeking medical care present with moderate-to-severe
AR,56-60 whereas in the general population they have mild AR.18
Severe chronic upper airway disease, as proposed by a joint
ARIA–Global Allergy and Asthma European Network
(GA2LEN)–World Allergy Organization expert group,61 isdefined by patients whose symptoms are inadequately controlled
despite adequate (ie, effective, safe, and acceptable) pharmaco-
logic treatment based on guidelines. These patients have an im-
paired quality of life, affecting social functioning, sleep, and
school/work performance.62 This concept of a patient-oriented
definition of severity has now been extended to all allergic
diseases by a Mechanisms of the Development of Allergy
(MeDALL)–GA2LEN-ARIA expert group.63
Phenotyping subtypes might characterize and predict disease
severity, progression, and response to treatment and might help
identify unique targets for treatment. Heterogeneity also exists
within each dimension of the disease (eg, eosinophils and asthma
severity),64 across diseases (eg, eosinophils in asthma), and in re-
lation to comorbidities.65 Phenotypes can change over time, pos-
sibly driven by allergic, infectious, or other triggers (PreDicta,
http://www.predicta.eu).ARIA STATEMENTS, POSITION PAPERS, AND
RECOMMENDATIONS
The ARIA expert panel has produced several recommenda-
tions, statements, and position papers, often in collaboration with
other organizations and/or the WHO Collaborating Center for
Asthma and Rhinitis (Montpellier) (Table I).61,66-69
ARIA has proposed stepwise guidelines (Fig 1).8ARIA 2010 REVISION
The ARIA 2010 Revision was developed following the
GRADE approach70 by the ARIA-GA2LEN guideline panel71
in total independence from the private sector.15 It summarized
the potential benefits and harms underlying the recommendations,
as well as assumptions around the values and preferences that
influenced the strength and direction of the recommendations.
Two independent methodologists developed evidence summa-
ries with the help of an information scientist with experience in
GRADE and 2 biostatisticians. Eight experienced clinician
members of the ARIA executive committee completed the panel.
Formulating the recommendations included consideration of
the quality of evidence, desirable and undesirable consequences
of following the recommended course of action, and values and
preferences of those for whom the recommendations are intended.
For most of the recommendations, resource use (cost) was also
taken into account.
Eighty health care practitioners (allergists; pediatricians; in-
ternal medicine; ear, nose, and throat or pulmonary specialists;
primary care physicians; nurses; and pharmacists) and patients
from more than 50 countries were consulted. As a result of input
received, additional bibliographic searches were performed for
more recent studies for 31 questions, and a newer consultation
was carried out to finalize the ARIA revision.
Taking into account both adults and children, a total of 59
recommendations were proposed: 11 for prevention, 31 for
pharmacotherapy, 11 for allergen-specific immunotherapy, 5 for
complementary and alternative medicine, and 1 for a biologic
(omalizumab, Table II).15
ARIA should be considered as a general guide, and physicians
need to tailor these general recommendations to individual
patients given that patients live in different environments and
each one has a different genetic makeup, responding differently to
allergens and medications.
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studies or only studies with a high risk of bias (Table II).15 Many
areas were identified requiring more rigorous systematic reviews
or updating of existing systematic reviews.
Real-life studies are needed to confirm that the applicability of
evidence obtained in randomized controlled trials (RCTs) trans-
lates into daily practice settings.72 Pragmatic randomized trials
have found that the guideline-based management of AR is more
effective than free treatment choice.56
Nonetheless, the ARIA guideline panel believes that the
recommendations reflect the best current treatment of patients
with AR.15
Studies need to be conducted in special populations, including
young children, elderly patients, patients with occupational AR
and asthma, and patients in low-resource countries.
After the publication of the ARIA revision, certain comments
by experts were published.73,74 It was not considered that these
comments should alter the conclusions published but rather that
they should enhance the transparency of the discussion around
the evidence.75DISSEMINATION AND IMPLEMENTATION
Guidelines need simplicity and educational outputs (ie, Web-
based activities [www.whiar.org, www.ariaenespanol.org],76
pocket guides, and questionnaires77), which are essential to facil-
itate implementation.78 The pocket guide, developed after the
ARIAWorkshop report, has been translated intomore than 50 lan-
guages. A version for the pharmacist has also been produced.79
The 2008 update executive summary has been translated into
more than 30 languages.80-88 In the United States, a group pro-
posed the adaptation of ARIA.89
All stakeholders, including specialists, primary care physi-
cians, health care professionals, patients, the public, and the
media, should be encouraged to use the guidelines and should be
involved in the production of guideline summaries and educa-
tional materials.
In many countries, ARIA guidelines are known by primary care
physicians and specialists.90,91GLOBAL APPLICABILITY OF ARIA AND UNMET
NEEDS
Many unmet needs for AR have been published. In this
document, unmet needs specific to ARIA are proposed from
existing ARIA documents.
1. AR phenotypes
d AR is strictly related to an immune-mediated mechanism,
and for inhalant allergy, it is restricted to an IgE-
mediated mechanism. However, nonallergic mechanisms
can be intertwined with allergic ones.
d Subphenotyping of AR: Applying (partly) unsupervised
statistical methods (eg, cluster analysis or factor analyses)
to a population will enable the definition of phenotypic
characteristics.
d Control of disease: Control and severity are not well delin-
eated in patients with rhinitis. Severe chronic upper airway
disease has defined patients with uncontrolled AR.61 Mea-
sures of AR control include symptom scores, visual analogscale scores,58 quality-of-life scores,8,92 or scores with sev-
eral items.93,94 Research should identify themost appropriate
AR control test that can be applied globally and in all settings.
d AR and asthma: Links between AR and asthma are well
known, but unsupervised statistical methods need to be
used to have a more objective view of the links.
d Pediatrics: ARIA documents have always considered pedi-
atric issues. However, AR is very often overlooked and
underdiagnosed, especially in preschool children.
d Elderly: Many patients with AR are older than 65 years.
The presentation of the disease as well as the efficacy
and safety of treatments can differ in older adults, but no
data are available. Moreover, the effect of comorbidities
on AR management is unclear.
d Personalized medicine: The main challenge for allergic dis-
eases in the 21st century is to understand their complexity.
The vast majority of patients with AR can be treated with a
simple algorithm, but a substantial number have uncon-
trolled symptoms during treatment62 and require a person-
alized (tailored) approach.2. Management of AR
d Update of the ARIA revision: Guidelines need to be contin-
uously updated with new published data and even new
treatments (eg, intranasal combination of H1-antihistamine
and corticosteroid95 or intranasal corticosteroids with an
hydrofluoroalkane propellant).
d ARIA in primary care: Most patients with AR are seen in
primary care, and guidelines should be adapted for this set-
ting.96-99 The adaptation of the ARIA 2010 Revision is on-
going in collaboration with the International Primary Care
Respiratory Group.
d Comparison of ARIA and other guidelines: Guidelines for
the management of AR differ somewhat because of the
classification of AR but also due to the recommendations
concerning treatment. It is of importance to compare the
different options and assess why these differences exist.
d Pharmacists and other health care practitioners: The major-
ity of AR medications are over the counter in most coun-
tries, but some over-the-counter drugs contain sedative
oral H1-antihistamines. It is important for pharmacists to
advise patients. Management of the allergic child at school
is also important.1003. Patient empowerment
Asthma and AR should be appropriately diagnosed and con-
trolled to satisfy patients’ expectations. Patients need to be involved
in their own care; this can be achieved through patient education
and self-management plans. Patient organizations have been in-
volved in the design, dissemination, and implementation of ARIA.4. Clinical trials
In RCTs, it is essential to have clarity with regard to definitions
of disease, severity, and control, as well as comorbidities and risk
factors (eg, smoking). RCT outcomes should be validated and
standardized, so that meaningful comparisons between RCTs can
be made.92
TABLE I. ARIA statements, position papers, and recommendations
d European Academy of Allergy and Clinical Immunology: ‘‘Requirements for medications commonly used in AR treatment.’’66
d GA2LEN–World Allergy Organization: ‘‘Unmet needs in severe chronic upper airway disease (SCUAD).’’61
d GA2LEN-WHO Collaborating Center: ‘‘Uniform definition of asthma severity, control, and exacerbations: document presented for the WHO Consultation on
Severe Asthma.’’67
d GA2LEN–WHO Collaborating Center: ‘‘Practical guide for skin prick tests in allergy to aeroallergens.’’68
d Mechanisms of the Development of Allergy (MeDALL)–GA2LEN–WHO Collaborating Center: Severe chronic allergic (and related) diseases: a uniform
approach (accepted for publication).
d GA2LEN: ‘‘How to design and evaluate RCTs in immunotherapy for allergic rhinitis.’’69
Allergen and irritant avoidance may be appropriate
Diagnosis of allergic rhinitis
If conjunctivitis
Add
  oral H1-blocker
  or intraocular H
1
-blocker
  or intraocular cromone
  (or saline)
Consider specific immunotherapy
Not in preferred order
 oral H
1
 blocker
 or intranasal H
1
-blocker
 and/or decongestant  
 or LTRA*
Mild
Intermittent
symptoms
Persistent
symptoms
Not in preferred order
 oral H
1
 blocker
 or intranasal H
1
-blocker
 and/or decongestant
 or intranasal CS
 or LTRA* 
 (or chromone)
In persistent rhinitis
review the patient
after 2-4 wks
If failure: step-up
If improved: continue
for 1 month
Mild
Moderate- 
severe
Failure 
referral to specialist
Moderate- 
severe
Failure
Review diagnosis
Review compliance
Query infections
or other causes
Add or increase
intranasal CS
dose
Rhinorrhea
add ipratropium
Blockage
add
decongestant
or oral CS
(short term)
Improved
Step-down
and continue
treatment
for > 1 month
Review the patient
after 2-4 wks
In preferred order
  intranasal CS
H
1
 blocker or LTRA*
Check for asthma
especially in patients with severe
and/or persistent rhinitis
FIG 1. Recommendations of the ARIA update (from Bousquet et al8). CS, Corticosteroid; LTRA, leukotriene
receptor antagonist.
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A uniform definition of AR is applicable to the local and
geographic conditions of all countries, phenotypes, and risk
factors. ARIA implementation in developing countries should
increase the availability and affordability of effectivemedications.6. Research
Further research into severe allergic diseases is urgently
needed to better understand the diseases and to providenovel therapeutic approaches. Global partnerships and platforms
should ensure the application of standard methodology
and protocols in the collection and sharing of samples and
data.677. Epidemiology
In epidemiology, standardized definitions are fundamental
for research, for the understanding of risk factors, and to
enable comparisons across studies in different populations.
TABLE II. ARIA revision (from Brozek et al15)
Prevention of
rhinitis or asthma
Management
of rhinitis
Management of
rhinitis and
comorbid asthma
No. of clinical questions analyzed
Total 11 39 9
Children 7 11 2
Adults 2 10 2
Not stated* 3 18 5
Quality of supporting evidence
High 0 4 1
Moderate 0 8 3
Low 5 11 2
Very low 6 16 2
Recommendation
High 3 6 1
Low 8 33 7
*Recommendation usually applicable to children and adults.
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6 BOUSQUET ET ALMechanisms of the Development of Allergy (MeDALL) has
developed a standardized AR definition for children (http://www.
medall-fp7.eu).8. Public health planning
In public health, a uniform definition of AR and severity
is needed to identify prevalence, burden, and costs; to
improve quality of care; and to optimize health care planning
and policies.9. Update of the ARIA revision
A conscientious analysis of the available evidence allows us
to conclude that the absence of moderate or high quality points
toward research gaps, particularly if it results in weak/condi-
tional recommendations. In the face of strong recommenda-
tions, the research gaps are less likely to influence action.10. Open access to ARIA membership
ARIA is open to all stakeholders globally, and requests for
membership should be addressed to the WHO Collaborating
Center for Asthma and Rhinitis (anna.bedbrook@inserm.fr).INTERACTIONS WITH THE PRIVATE SECTOR
The private sector has been involved in ARIAwith the status of
observer, as described according to the WHO Global Alliance
Against Chronic Respiratory Diseases (GARD) (http://www.
who.int/gard):
d industry associations/umbrella organizations representing
manufacturers of diagnostic reagents, devices, drugs, or
other products or services relevant to the surveillance, pre-
vention, and control of allergic and respiratory diseases and
d commercial enterprises and private sector entities.
The role of ‘‘observer’’ is also based on WHO Global Alliance
Against Chronic Respiratory Diseases (GARD) (http://www.
who.int/gard):
d There are no rights in the decision-making process, partic-
ularly in guideline development.d Observers can make statements to present their views or
positions on a specific issue only on invitation of the chair-
man (after agreement with the executive committee).
d The private sector is associated to the implementation and
dissemination of ARIA.
ARIA IN THE POLITICAL AGENDA
ARIA was initiated during a WHO workshop (1999) and
published in collaboration with WHO. It was then involved in the
activities of the WHO Collaborating Center for Asthma and
Rhinitis (Montpellier). The 2008 Update was carried out in
collaboration with WHO, GA2LEN (Framework Programme 6),
and AllerGen (the Canadian network on allergy).
The European Medical Agency has accepted the ARIA clas-
sification of intermittent and persistent rhinitis.
ARIA has been used in several guidelines recommended by
governmental health agencies (eg, Brazil, Portugal, Singapore,
and the Finnish Allergy Plan101) or scientific societies. In certain
countries, Health Technology Assessment is being started by us-
ing the ARIA 2010 Revision in collaboration with the Canadian
Society for International Health.
The leading priority for the 2011 Polish Presidency of the
Council of the European Union is to reduce health inequalities
across European societies and, within its framework, to improve
prevention and control of respiratory diseases in children.102,103
ARIA research will strengthen the conclusions of the priority to
reduce the burden of allergy and asthma in children for an im-
proved active and healthy aging.REFERENCES
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